A Dallas-based clinical laboratory, its owners, and its investors have agreed to pay a combined $24 million to resolve serious federal allegations involving pandemic-era testing fraud that allegedly exploited vulnerable seniors seeking routine COVID-19 screening.
According to the U.S. Department of Justice, Magnolia Diagnostics, alongside owners John Bains and Kelly Bains, will pay $19.2 million to resolve claims that they violated the False Claims Act. The government alleged that the company billed Medicare for thousands of medically unnecessary respiratory pathogen panel (RPP) tests performed on seniors who were simply seeking COVID-19 screening. In a notable move for federal enforcement, the laboratory's investors will also pay an additional $4.8 million to resolve claims for unjust enrichment and payment by mistake arising from financial distributions they received as a result of the alleged scheme.
The Alleged Scheme | Leveraging COVID-19 Tests for Profit
The government's allegations paint a picture of a company prioritizing profit over patient care during the height of a global health crisis. According to federal investigators, starting in April 2020, Magnolia Diagnostics devised a strategy to aggressively market to senior living communities. When facilities requested necessary COVID-19 tests for their residents, the lab allegedly required them to also accept highly expensive respiratory pathogen panels, regardless of whether the individual patients actually exhibited symptoms requiring such extensive testing.
The DOJ outlined several specific tactics allegedly used to execute the scheme:
- Pre-Populated Forms: The lab reportedly used requisition forms with the expensive RPP tests and associated diagnosis codes pre-selected before any clinical evaluation occurred.
- Blanket Authorizations: Magnolia allegedly treated single provider signatures as blanket orders to test entire communities, bypassing the requirement for individualized clinical necessity.
- Coercion and Altered Documents: The government alleged that John Bains threatened to completely withhold vital COVID-19 testing from facilities that refused the additional RPP tests. Investigators also claimed that on at least two occasions, provider-signed forms were altered to expand the scope of testing to other, unauthorized facilities.
Frozen Specimens and Delayed Results
Perhaps the most troubling allegation centered on the lab's handling of the physical testing specimens. The DOJ claimed that Magnolia Diagnostics froze and stored thousands of respiratory specimens, sometimes for weeks or months, before eventually thawing and testing them. By the time these delayed results were generated and billed to Medicare, they were completely useless for informing timely treatment, isolation, or infection-control decisions for the vulnerable senior population.
"We will pursue not only companies that submit false claims and the owners who direct the misconduct, but also investors who receive and retain its financial benefits, especially when vulnerable Americans are exploited for profit," stated Assistant Attorney General Brett A. Shumate of the Justice Department's Civil Division.
It is important to note that the claims resolved by the settlement are allegations only, and there has been no formal determination of liability. The settlement does, however, represent one of the more significant pandemic-era healthcare fraud resolutions involving a Dallas-based laboratory, and the inclusion of investor payments signals that the DOJ is willing to pursue financial beneficiaries beyond the corporate entity and its named owners.
For more Texas investigations and healthcare fraud coverage, see the oWire Greater Texas hub or read our reporting on the $400M Georgetown fraud verdict.